Original language | English |
---|---|
Pages (from-to) | 204-213 |
Number of pages | 10 |
Journal | Journal of Thoracic Disease |
Volume | 15 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2023 |
Keywords
- Empathy
- connection
- lung cancer
- patients
- thoracic surgery
- vulnerability
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Thoracic Disease, Vol. 15, No. 1, 01.2023, p. 204-213.
Research output: Contribution to journal › Editorial
TY - JOUR
T1 - Sawubona reprise
T2 - reflections on the European Society of Thoracic Surgeons Presidential Address 2022
AU - Brunelli, Alessandro
AU - Argyriou, Amerikos
AU - Batirel, Hasan
AU - Colson, Yolonda
AU - Darling, Gail
AU - Fernandez, Felix
AU - Gooseman, Michael
AU - Lerut, Toni
AU - Molena, Daniela
AU - Novoa, Nuria
AU - Opitz, Isabelle
AU - Papagiannopoulos, Kostas
AU - Patterson, G. Alexander
AU - Petersen, Rene H.
AU - Rawlinson, Janette
AU - Rocco, Gaetano
AU - Stiles, Brendon M.
AU - Tariq, Javeria
AU - Varela, Gonzalo
N1 - Funding Information: Merck, and Genentech. IO reports that no real conflicts of interest are related to the work. The following could be perceived as such: Roche (Institutional Grant and Speakers Bureau), AstraZeneca (Advisory Board and Speakers Bureau), MSD (Advisory Board), BMS (Advisory Board), Medtronic (Institutional Grant), Intuitive (Proctorship). KP serves as an unpaid Editorial Board Member of Journal of Thoracic Disease. RHP serves as an unpaid Editorial Board Member of Journal of Thoracic Disease and is a member of the advisory board for AstraZeneca, Roche, MSD. RHP received speaker fee from Medtronic, AMBU, Medela, AstraZeneca. JR reports that she is involved with a number of lung cancer groups, charities and organisations in UK and Europe, as a patient partner in research/public patient partner voice. She holds no leadership roles e.g., Chair. The Patient public voice role is an equal member in the duties and responsibilities of those committees. All have policies of reimbursing travel/accommodation to ensure that nobody is left out of pocket by taking part in research. Some offer honoraria. Very few meetings have taken place in person during the pandemic in person therefore travel reimbursement has been minimal. Her CCG role was a fiduciary role as an equal member of the board. As an independent, she is repaid as an individual. GR received royalties from Scanlan International and he is a member of the advisory board for AstraZeneca. BMS received grants from Bristol Myers Squibb and Bristol Myers Squibb Foundation, and consulting fees from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche-Genentech, Arcus Biosciences, Galvanize Therapeutics, Medtronic. BMS is the inventor of patents TARGETING ART1 FOR CANCER IMMUNOTHERAPY (Patent Application Serial No. 63/307,502, filed February 7, 2022). BMS is a member of the Steering Committee for Medtronic for Medtronic, Data Safety Monitoring Board for Galvanize Therapeutics, Trial Steering Committee/Data Monitoring and Ethics Committee for RAMON study, Scientific Advisory Board for LUNGevity, Board and Vice Chair for Lung Cancer Research Foundation. BMS’s spouse receives personal fees for salary from Xalud Therapeutics and owns stock, and options in Xalud Therapeutics, and stock in Pfizer. The other authors have no conflicts of interest to declare.
PY - 2023/1
Y1 - 2023/1
KW - Empathy
KW - connection
KW - lung cancer
KW - patients
KW - thoracic surgery
KW - vulnerability
UR - http://www.scopus.com/inward/record.url?scp=85146675846&partnerID=8YFLogxK
U2 - 10.21037/jtd-22-1550
DO - 10.21037/jtd-22-1550
M3 - Editorial
C2 - 36794145
AN - SCOPUS:85146675846
SN - 2072-1439
VL - 15
SP - 204
EP - 213
JO - Journal of Thoracic Disease
JF - Journal of Thoracic Disease
IS - 1
ER -